This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Phase II Trial of Allovectin-7® for Head and Neck Cancer

This study has been completed.
Information provided by:
Vical Identifier:
First received: December 6, 2002
Last updated: June 20, 2008
Last verified: June 2008
The purpose of this clinical trial is to determine if Allovectin-7®, an experimental gene-based immunotherapy, can shrink head and neck tumors. The trial will also examine if treatment can boost the immune system and if this treatment can improve the time to disease progression.

Condition Intervention Phase
Head and Neck Cancer Squamous Cell Carcinoma of the Oral Cavity or Oropharynx Head and Neck Neoplasms Carcinoma of the Head and Neck Genetic: Allovectin-7® Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase II Study of the Safety and Efficacy of Allovectin-7® Immunotherapy for the Treatment of Primary, Resectable Squamous Cell Carcinoma of the Oral Cavity or Oropharynx

Resource links provided by NLM:

Further study details as provided by Vical:

Estimated Study Completion Date: June 2002
Detailed Description:
Treatment - If you take part in this trial you will be treated for about four weeks. You will receive an injection of Allovectin-7® by needle, directly into your tumor. This will be repeated 14 days later. The injections may be given in a doctor's office. A week later, you will undergo surgery to remove the tumor. Your tumor will be measured before Allovectin-7® treatment and before surgery to see if Allovectin-7® was effective in shrinking it. This will be done by general physical exams and scans (such as X-ray scans). There will also be tests on the removed tumor to see if Allovectin-7® helped to boost the immune system to attack the cancer.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

In order to be in this trial, you must meet the enrollment criteria. Below is a list of some of the enrollment criteria.

  • You have been diagnosed with head and neck cancer (also called squamous cell carcinoma of the mouth)
  • You have Stage I or Stage II disease (a single mouth tumor which has not spread to other areas of the body)
  • Surgery to remove your tumor is recommended
  • You have not received any prior therapy for head and neck cancer (e.g. radiation or chemotherapy)
  • You are able to carry out your normal daily activities
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00050388

United States, Alabama
University of Alabama, Birmingham
Birmingham, Alabama, United States, 35233
United States, Arkansas
University of Arkansas for Medical Sciences
Little Rock, Arkansas, United States, 72205
United States, Florida
H. Lee Moffitt Cancer Center & Research Institute
Tampa, Florida, United States, 33612
United States, Illinois
University of Chicago
Chicago, Illinois, United States, 60637
United States, Louisiana
Louisiana State University
New Orleans, Louisiana, United States, 70112
United States, Michigan
University of Michigan Medical Center
Ann Arbor, Michigan, United States, 48109
Henry Ford Health System
Detroit, Michigan, United States, 48202
United States, Ohio
University Cincinnati Medical Center
Cincinnati, Ohio, United States, 45267
Case Western Reserve University
Cleveland, Ohio, United States, 44106
United States, Pennsylvania
University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104
Sponsors and Collaborators
  More Information Identifier: NCT00050388     History of Changes
Obsolete Identifiers: NCT00028457
Other Study ID Numbers: VCL-1005-207
Study First Received: December 6, 2002
Last Updated: June 20, 2008

Keywords provided by Vical:
Head cancer
Neck cancer
Tongue cancer
Lip cancer
Oral Cavity
Squamous Cell
Salivary Glands
Cancer treatment
Clinical trial
Otorhinolaryngologic Neoplasm
Otolaryngologic Cancer
Gene therapy
Cancer research
Cancer vaccine
Cancer cells

Additional relevant MeSH terms:
Carcinoma, Squamous Cell
Head and Neck Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms, Squamous Cell
Neoplasms by Site processed this record on June 23, 2017